Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00864669 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00864669: Completed Phase 1 study, sponsored by Actavis.
NCT00864669 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00864669, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co. with that of 500 mg CLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 500 mg extended-release tablet) in healthy adult volunteers under non-fasting conditions.
Interventions
- DRUG Metformin HCl 500 mg tablets, single dose
- DRUG CLUCOPHAGE® XR 500 mg tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2002-03 |
| Est. Completion | 2002-03 |
| Phase | Phase 1 |
What the finished NCT00864669 record still lists
NCT00864669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Metformin HCl 500 mg tablets, single dose is the first listed.
NCT00864669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00864669 about?
NCT00864669 is a clinical study titled "A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions". The purpose of this study is to compare the relative bioavailability of 500 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co. with that of 500 mg CLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 500 mg extended-release tablet) i...
What is the current status of trial NCT00864669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2002-03. Estimated completion is 2002-03.
What interventions are being tested in trial NCT00864669?
The interventions under investigation include: Metformin HCl 500 mg tablets, single dose (DRUG), CLUCOPHAGE® XR 500 mg tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT00864669?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00864669's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia